presentación nucleo uct 2012 ii

Post on 20-Jun-2015

231 Views

Category:

Business

3 Downloads

Preview:

Click to see full reader

TRANSCRIPT

Plantas medicinales y terapias alternativas en Alzheimer. Una tierra desconocida

Laboratorio de Fisiología de la Reproducción

Jorge Parodijparodi@uct.cl

http://www.alz.org/alzheimers_disease_alternative_treatments.asp

Caprylic acid and coconut oil ConcernsCoenzyme Q10Coral calciumGinkgo bilobaHuperzine AOmega-3 fatty acidsPhosphatidylserineTramiprosate

Conclusion Compared with placebo, the use of G biloba, 120 mg twice daily, did not result in less cognitive decline in older adults with normal cognition or with mild cognitive impairment.

Snitz et al 2009 JAMA

Test Placebo Ginko

Memory 0,15 0,14

Executive test 3,27 3,47

Date of download: 7/14/2012Copyright © 2012 American Medical Association.

All rights reserved.

From: Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease:  A Randomized Trial

JAMA. 2010;304(17):1903-1911. doi:10.1001/jama.2010.1510

Danitz and Parsons 2008 IJNP

Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease

Conclusions In patients with moderate or severe Alzheimer's disease, continued treatment with donepezil was associated with cognitive benefits that exceeded the minimum clinically important difference and with significant functional benefits over the course of 12 months JAMA 2012

Palmer 2002 Trends in Phar

Benilova et al 2012 Nature Neuroscience

Agregados Ab1-40 se localizan en regiones sinápticas

Ab – DAC (1:2)24 horas0.5 mM

MAP1B – Cy3 A

Ab - DAC B

SV2 – Cy5 C G

H

10 mm

D

H

G

Parodi et al (2010) JBC

Savonenko et al (2005) Neurobiology of Disease

Dinamarca et al (2006) Molecular Psychiatry

Inestrosa et al (2011) Translation Psychiatry

Montesinos et al (2012) in report

Modeling

0 50 100 150 200

0,0

0,2

0,4

0,6

0,8

1,0

1,2

Tiempo (min)

Tu

rbim

etri

a (D

.O. 4

05 n

m)

Control 5 mM Etanol 10 mM Etanol 50 mM EtanolA B

C D E

Ormeño et al (2012) in review

C

BA

D

A

ASP-23

LYS-28

B

ASP-23

LYS-28

2.7Ẳ

ASP-23

LYS-28C

12.7Ẳ

D

ASP-23

LYS-28

6.3Ẳ

0,0 0,5 1,0 1,5 2,0 2,50

2

4

6

8

10

12

Time (ns)

Control Ethanol 10 %

A

0,0 0,5 1,0 1,5 2,0 2,5

0

5

10

15

20

25 Control Ethanol 1%

Dev

iation (R

MSD

) Time (ns)

B

Control

Trata

das 1 5 10 25 50 100

0,0

0,5

1,0

1,5

2,0

2,5

*

*

**

Etanol (mM)

Agregados amilodes

Fre

cuen

cia

(Hz)

Act

ivid

ad S

ináp

tica

Esp

on

tán

ea

Control

Agregados A 0.5 M (24 h)

Agregados A 0.5 M + 10 mM Etanol (24 h)

Agregados A 0.5 M + 50 mM Etanol (24 h)

50 mM Etanol (24 h)

0.2 s 20 p

A

0.2 s 20 p

A

0.2 s 20 p

A0.2 s 20

pA

0.2 s 20 p

A

Sv2

Control

Aaggregates 0.5 M

Aβ aggregates 5 M

Aβ aggregates 10 M

10 mM etanol

50 mM etanol

Aaggregates 0.5 M

Ormeño et al (2012) in review

-6 -5 -4 -3 -2 -1 0 10,0

0,5

1,0

1,5

Num

ber

of events

Amplitude (nA)

Control Gramicidin Amphotericin B Aggregate

A B C

-200 -150 -100 -50 0 50 100

-8

-6

-4

-2

0

2

4

6

8

nA

mV

Aggregate Gramicidin Amphotericin Control

Contro

l

Gramicidin

Amph

otericin B

Aggr

egates

0

-200

-400

-600

-800

-1000

**

Mem

bra

ne c

onducta

nces (nS

)

*

Parodi et al (2012) in review

B

C

A

D

+ 20 mV0 mV

Control

Aggregate

High Ca2+

NR

High Ca2+

NR

-100 mV

+ 20 mV0 mV

-100 mV

100 nA250 ms

4 min

200

nA

Rabbit serum

15 min Aggregate

0 min 15 min

NR

0

50

100

150

200

250

300

Aggregate

High Ca2+NR

*

*

Curr

ent a

mplit

ude

(% o

f co

ntr

ol a

t +20

mV)

*

NR High Ca2+

0

50

100

150

200

15 min Aggregate15 min

*

Curr

ent am

plit

ude

(% o

f co

ntr

ol ) NR

0 min

20

0 n

A

60 s

100 μM ATP0 min 15 min

15 min AggregateNR

0

20

40

60

80

100

120

15 min Aggregate15 min

Cu

rre

nt

(% o

f c

on

tro

l)

0 min

*

AgradecimientosDr. Luis AguayoDr. Nibaldo InestrosaFernando SepulvedaDavid Ormeño

Laboratorio de Fisiología de la ReproducciónFelipeGuillermoDaniela

ColaboradoresDr. Alexander OrtloffMsC Patricio Peña

top related